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Abstract: Diffusion-weighted imaging (DWI) is the most effective component of the modern
multi-parametric magnetic resonance imaging (mpMRI) scan for prostate pathology. DWI provides
the strongest prediction of cancer volume, and the apparent diffusion coefficient (ADC) correlates
moderately with Gleason grade. Notwithstanding the demonstrated cancer assessment value of DWI,
the standard measurement and signal analysis methods are based on a model of water diffusion
dynamics that is well known to be invalid in human tissue. This review describes the biophysical
limitations of the DWI component of the current standard mpMRI protocol and the potential for
significantly improved cancer assessment performance based on more sophisticated measurement
and signal modeling techniques.
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1. Introduction
Prostate cancer is estimated to account for the deaths of 30,000 Western men annually [1];
however, many forms of prostate cancer are indolent and do not require treatment. Using only
traditional assessment techniques it remains unclear and controversial as to which men require
aggressive treatment and what form it should take. While the tumour’s grade and volume are
the best indicators of malignancy, and thus the need for intervention, at present these can only be
reliably measured after surgical removal of the prostate [2–4]. Transrectal ultrasound guided (TRUS)
biopsy, the standard diagnostic method, has low sensitivity and often underestimates malignancy [5–7].
Prostate specific antigen (PSA) screening has increased the rate of prostate cancer detection but resulted
in a large number of men with clinically insignificant disease undergoing unnecessary treatment [8,9].
Treating insignificant prostate cancer inflicts otherwise avoidable pain, stress, cost, and complications
including impotence and incontinence. There is now a significant discrepancy between the potential
of localized therapy and the targeting information available on disease localization. A recent report
describes real time motion-compensated delivery of a radiotherapy beam with precision better than
1 mm [10]. Unfortunately, for prostate cancer patients, there is currently no correspondingly precise
tumour imaging technique to plan the focal or boosted dose delivery which would maximize treatment
effect while causing minimum harm to uninvolved tissues within and adjacent to the prostate.
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2. Multiparametric Magnetic Resonance Imaging (mpMRI)
2.1. mpMRI and Prostate Cancer
Better pretreatment imaging of prostate cancer is critical to reducing unnecessary treatment of
insignificant disease while improving the effectiveness and minimizing the harm of interventions.
The current best imaging method, multiparametric magnetic resonance imaging (mpMRI), is increasingly
being used to target biopsies, assess risk, and select treatment. The mpMRI protocol comprises three
independent scans with distinct image contrast mechanisms. Each scan depends on a particular
property of tissue water: (1) T2 on the molecular environment of the water; (2) dynamic
contrast enhancement (DCE) on blood flow and vessel wall permeability; and (3) DWI on tissue
microstructure [11–13]. Radiologists interpret the T2, DCE, and DWI scans to report on the probable
amount and location of any cancer. The PI-RADSTM reporting standard [14] aims to minimize
image interpretation subjectivity, and there are UK and European consensus statements relating
to standardization of imaging method [15,16].
2.2. The Role of Diffusion-Weighted Imaging in mpMRI
The DWI component of the mpMRI scan has far stronger correlations with both cancer grade
and volume than T2 and DCE [17–19]. This superior performance of DWI relates to the direct
dependence of image contrast on differences in the rate of diffusion of water molecules due to tissue
microstructure changes. Cancer-associated changes (including the number, size, type, and arrangement
of cells) significantly alter the water diffusion behavior. The common categorization of DWI as
a ‘functional’ imaging technique is an unfortunate misnomer—no other MRI contrast mechanism is
more closely related to tissue structure.
3. What is DWI Measuring?
3.1. Diffusion-Sensitization of the MRI Signal
The basic DWI method produces a signal that is dependent on the average water molecule
displacement over a specific time interval in a direction defined by a pair of ‘diffusion-sensitizing’
magnetic field gradients [20]. Larger average displacements within a voxel (measurement volume element)
result in greater DWI signal attenuation. The displacement sensitivity of the DWI measurement
can be increased either by increasing the time interval between the diffusion-sensitizing gradients
(the ‘effective diffusion time’), or by increasing the strength of the gradients. These two independent
imaging method parameters are commonly combined and expressed as the diffusion-weighting or
‘b-factor’ (or b-value).
Depending on the measurement technique, signal attenuation may result from both ‘true’ diffusion
(Brownian thermal motion) and flow due to tissue perfusion. The recommended mpMRI protocols [15,16]
aim to minimize perfusion effects so that the image contrast relates primarily to the way the tissue
microstructure hinders and restricts thermal diffusion. Structurally dense tissue (typical of solid
non-necrotic tumours) appear brighter in the diffusion-weighted image than normal tissues with
relatively loosely packed cells and an open extracellular matrix. By performing multiple measurements
with an array of diffusion-sensitizing gradient orientations the presence and degree of diffusion
anisotropy (preferential diffusion in a particular direction) can be quantified. Post-processing of
anisotropy data from multiple voxels in a 3D volume enables the mapping and visualization of
fiber tracts.
An important but often neglected feature of DWI is the sensitivity to tissue structure on multiple
spatial scales. Depending on the time interval of the diffusion-weighted measurement each water
molecule is likely to ‘explore’ a larger or smaller range of spatial scales of the tissue microstructure.
For long diffusion times structure heterogeneity on the smallest spatial scales will be averaged out and
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the signal attenuation will depend primarily on large scale tissue structure features. Conversely, at the
short time limit there are minimal interactions with the tissue structure and molecular displacement
has the Gaussian probability distribution of unhindered Brownian motion. For clinical DWI scans
typical diffusion times are around 40–80 ms, corresponding to an unhindered unrestricted mean
diffusive water displacement of about 30 µm. By assessing the dependence of signal attenuation on
diffusion time it is possible to estimate the dimensions of restricting structures.
The direct dependence of water mobility on the tissue microstructural environment means DWI
is sensitive to the arrangement, type, geometry, and permeability of cells at the micron scale—key
characteristics that correlate with cancer malignancy.
3.2. Signal Models
The inference of specific tissue structure changes from DWI measurements presents a significant
and only partially tractable inverse problem. While it is well established that tissue microstructure
affects molecular diffusion dynamics, and hence the degree of attenuation of a diffusion-weighted
MRI signal, many different tissue structures could potentially lead to the same average water molecule
displacement and the same DWI signal. The number of solutions to this inverse problem, and thus the
sensitivity and specificity for pathology detection, depends on the information content of the DWI
measurement (the data acquisition method) and the ability of the signal analysis model to extract this
information (the data processing method).
DWI signal models can be categorized broadly as either phenomenological or structural.
Phenomenological models aim for a reliable mathematical description of the DWI signal attenuation
as a function of increasing diffusion weighting. Structure-based models predict the DWI signal
attenuation based on calculated or simulated diffusion dynamics in one or several structural
compartments. The recent historical trend is towards structure-based models as, ideally, the model
parameters correspond directly to diagnostic tissue structural features. At present the recommended
DWI protocol for prostate mpMRI uses only the very simple phenomenological ‘ADC’ model.
4. Limitations of the Standard ‘Apparent Diffusion Coefficient’ (ADC) Model
4.1. The ‘Apparent Diffusion Coefficient’ (ADC)
Cancer detection and characterization using clinical DWI methods is currently almost exclusively
based on a model that assumes a Gaussian displacement probability for water and a consequent
monoexponential decay of the DWI signal (S) with increasing diffusion weighting (b).
S = S0e−Db (1)
where D is the water self-diffusion coefficient. Because tissue constitutes a highly heterogeneous
diffusion environment and the displacement probability is generally non-Gaussian, D is conventionally
replaced by ADC—an apparent diffusion coefficient. The use of the indefinite article ‘an’ here is important.
The calculated value of ADC may be strongly dependent on both the DWI measurement protocol and
the model fitting method, although this is generally not recognized in the radiology literature [21].
The monexponential ADC model is the simplest possible description of DWI signal behavior, and
thus a very poor solution to the inverse problem of assessing tissue structure from a DWI measurement.
Calculation of a tissue ADC map provides a semi-quantitative assessment of gross variations in water
diffusion dynamics due to factors that may include cell density, size, shape, permeability, subcellular
architecture, extracellular matrix, and perfusion effects. The dependence of ADC on a variety of
histological features simultaneously means it lacks biological specificity.
Despite its simplicity the ADC model performs well compared with other MRI contrast methods
for prostate cancer detection and grading. There is a moderate negative correlation between ADC and
cancer Gleason grade [22,23], and ADC correlates more strongly with histologically determined cancer
Diagnostics 2016, 6, 21 4 of 13
volume than T2 and DCE parameters [17]. Nevertheless, reported ADC values in prostatic cancer and
benign tissue overlap substantially, particularly in the central and transition zones [24,25].
4.2. ADC Variations in Prostate Tissue at the Microstructure Scale
Diffusion-weighted magnetic resonance microimaging of formalin fixed prostate tissue has
revealed distinctly different diffusion dynamics in the three major gland components. ADC is low in the
epithelium, higher in the fibromuscular stroma, and highest in lumen space [26]. Diffusion anisotropy
is high in the fibromuscular stroma, and low in the epithelium layer and lumen space [27]. In the stroma
the preferential diffusion direction matches the orientation of the smooth muscle cells [27]. Changes in
the relative partial volume of these gland components appears to be the most significant contributor to
ADC differences detected at the spatial resolution typical of clinical prostate scans (see Section 4.3).
Low ADC epithelium has also been found in breast [28] and esophagus [29] tissue; however,
the biophysical basis of ADC differences between epithelium and stroma is yet to be elucidated.
4.3. ADC and ‘Cellularity’
Cancer-related changes in DWI signal contrast and ADC are conventionally attributed to tissue
‘cellularity’ variations. The commonly reported cellularity metrics are nuclear count per unit area in
a histological image, and nuclear area per unit area. While there is substantial evidence for a correlation
between these metrics and ADC in neural tissue, there is very limited biophysical evidence that in
cancer tissue a higher cell density will, per se, result in ADC changes. Besides cell density, membrane
permeability and multiple intra- and extracellular structural features will affect the measured ADC.
In the prostate, cell type may be more important than cell density. In fixed whole prostates, both
ADC and Gleason pattern changes correlate more strongly with relative partial volume of the gland
components epithelium, stroma, and lumen than with cellularity metrics [30].
5. Improving on ADC—Phenomenological Models
5.1. DTI: A Simple Anisotropic Model
Diffusion tensor imaging (DTI) extends the isotropic, monoexponential ADC model to account
for diffusion anisotropy. ADC is replaced by a 3× 3 symmetric tensor D. The extra degrees of freedom
allow the model to detect anisotropy when there is underlying microstructure with a high degree of
structural order. D summarizes the principal diffusion directions (eigenvectors) and corresponding
diffusivities (eigenvalues λ1 ≥ λ2 ≥ λ3). One of the most commonly used metrics derived from the
tensor is the fractional anisotropy (FA) which indicates the degree of any anisotropy:
FA =
√
(λ1 − λ2)2 + (λ1 − λ3)2 + (λ2 − λ3)2
2(λ21 + λ
2
2 + λ
2
3)
(2)
Clearly, there are many nonidentical tensorsD that could have identical FA values, emphasizing that
FA is a non-specific marker of microstructural order.
At the tissue microstructure scale regions of coherent myocyte orientation in prostate
fibromuscular stroma give rise to distinct diffusion anisotropy [27,31]. However, in vivo DTI studies
of the prostate have yielded inconsistent results for the value of FA in predicting the presence of
cancer [32–37]. Some of this inconsistency likely results from method variations and the well-known
sensitivity of FA to measurement noise [38,39]. Further, at typical clinical imaging spatial resolutions
(voxel volume 4–16 mm3), incoherent smooth muscle orientation within individual voxels would be
expected to reduce the measured FA. A study of whole prostates ex vivo demonstrated a consistent
and continuous decrease in FA as voxel volume increased, and very large differences in average FA
between prostates [40].
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Such equivocal results highlight the weakness of the DTI model for describing prostatic tissue,
and as a recent study suggests [41], anisotropy may be more informative and reliable as part of
a multicompartment model (see Section 7.2).
5.2. Higher Order Isotropic Models
The non-monoexponential DWI signal attenuation with increasing b-factor has been characterized
with a range of mathematical models of variable complexity (see Section 6 for methods of
comparing models). The simplest of these assesses the kurtosis of the signal attenuation, or how
it deviates from a monoexponential [42]:
S = S0e−(DKb−
K
6 D
2
Kb
2) (3)
In this model the ADC is replaced by a kurtosis-adjusted diffusivity (DK). The kurtosis (K)
has no biophysical interpretation, but has been reported to provide more accurate cancer detection
(higher area under an ROC curve) than ADC [43,44].
For DWI measurements that include very high diffusion weightings a biexponential model
is preferred:
S = S1e−D1b + S2e−D2b (4)
This is basically a ‘two ADCs’ model and can be interpreted to represent two distinct pools of water,
though the temptation to assign the pools to specific tissue compartments should be resisted [45].
The biexponential is the basis of the ‘IVIM’ (intravascular incoherent motion) model [46] that can
be used for measurements that include intermediate and very low diffusion weightings and thus
may be significantly affected by tissue perfusion. In this instance the very high ADC of one of the
water components enables its unequivocal assignment to blood flow rather than thermal diffusion.
The IVIM model has shown inconsistent results for prostate cancer assessment. While some studies
found poor diagnostic value compared to ADC [47–49], others report significant differences between
the IVIM parameters for benign and cancer tissue [50,51]. Perhaps surprisingly, there appears to be
no consistent agreement between the characteristics of the perfusion attenuated signal and dynamic
contrast enhancement (DCE) model parameters. One study reported lower perfusion fractions in
cancer tissue [49], contrary to DCE-MRI studies and expected tumour angiogenesis, while another
found opposite correlations [52].
The stretched exponential model assumes that tissue microstructure heterogeneity results in the
the presence of a large number of Gaussian components each with different diffusivities [53]:
S = S0e−(Dsb)
α
(5)
where α is the ‘stretching factor’ and Ds is a ‘stretch-adjusted’ diffusivity.
Phenomenological models permit only limited physical interpretation, however, by comparing
the theoretical information content of different signal models applied to the same measurement data
(see Section 6.2) it is possible to make general inferences about underlying tissue structure.
6. Model Selection and Performance Testing
Phenomenological models of prostate DWI have generally been compared either by assessment of
their cancer prediction performance or by estimation of their relative theoretical information content.
6.1. Correlation of Model Parameters and Tissue Pathology
A major weakness of almost all of the studies that compare models on the basis of cancer prediction
performance is that the common practice is to correlate individual parameters of multi-parameter
models with pathology. In this instance only a fraction of the model’s information content is being
tested and the implicit purpose of using a higher order model may be defeated, except in the
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fortuitous and unpredictable circumstance when a particular parameter contains most of the diagnostic
information. Only very recently have a few authors begun to assess the predictive value of parameter
combinations and thus incorporate all model information [54].
6.2. Model Ranking Based on Information Theory
As an alternative to pathology detection performance, especially in the absence of large sample
sizes and reliable correlation of imaging and histopathology ‘truth’ data, competing DWI data models
can be compared in terms of their theoretical information content. The implicit assumption of this
approach is that a higher information content implies greater microstructure prediction accuracy from
a specific set of measurement data (see Section 6.3).
A highly parameterized model will in general always fit a given data set more closely (‘better’)
than a model with fewer parameters. But do the extra model parameters have any physical meaning
in terms of the measured system? Applied to the problem of model selection from inevitably
noisy measurement data, information theory aims to balance the inherent parameter bias of overly
simplistic models against ‘overfitting’ and consequent high parameter variance of highly parameterized
models [55]. The Akaike Information Criterion (AIC) [56], and similar Baysian Information Criterion [57],
provide an estimate of the relative distance of competing models from an unknowable ‘truth’. In the
specific case of water diffusion in biological tissue the truth is immensely complex and the best we can
aim for is a diagnostically informative approximation.
Applied to prostate DWI, the information theory approach demonstrates that in whole organs
examined ex vivo (eliminating perfusion effects) with a wide range of diffusion weightings the
3-parameter biexponential model has a significantly higher information content than 1-parameter
ADC, and 2-parameter kurtosis and stretched exponential models [45]. This result enables the general
inference that there exist two water diffusion environments with distinct ‘structure densities’ leading
to two different apparent diffusion coefficients. The comparatively low information content of the
ADC, kurtosis, and stretched exponential models indicates that there is not simply one heterogeneous
structural environment leading to a continuum of diffusion coefficients. In vivo prostate DWI studies
support the existence of two diffusion environments distinct from the vasculature [58,59]. Application of
the stretched exponential model to the individual components of the biexponential model demonstrates
the two distinct diffusion environments are internally heterogeneous [60], but further basic science
studies are required to identify these environments histologically. These results, while providing some
insight into the complexity of water diffusion dynamics in prostate tissue, highlight the current absence
of a clear biophysical understanding of the mechanisms of a powerful clinical imaging technique.
6.3. The Importance of Imaging Method
Whatever approach is used for model selection it is important to note that the imaging protocol
is critical. With a given set of measurement data the best model is conceptually the one that extracts
most information from the inevitably noisy data, and practically the one that provides the most
accurate (sensitive and specific) pathology prediction. If the imaging protocol is inappropriate
then the measurement data will not contain information that predicts pathology. Improving the
clinical performance of DWI thus depends on optimization of both the measurement technique and
the signal analysis model. Because of the inherently low signal-to-noise ratio of MRI in general,
and DWI in particular, there are significant technical, practical, and financial constraints on obtaining
an information-rich measurement.
For prostate DWI, imaging method considerations appear in a plethora of research publications
around the theme of an ‘optimum b-factor’ for cancer detection. Unfortunately, as mentioned in
Section 3.1, the importance of diffusion time in defining the structure-scale sensitivity of the imaging
method is generally not recognized and diffusion times are very rarely reported. Different MRI
scanners are likely to generate the same b-factor according to the available maximum gradient strength
Diagnostics 2016, 6, 21 7 of 13
(which may vary widely between scanners) and thus using very different diffusion times [21]. As yet,
the diffusion time-dependence of ADC measurements in prostate tissue has not been investigated.
6.4. Model-Based Image Synthesis
Because of reports that acquisitions performed with higher b-factors have greater cancer detection
accuracy there has been strong recent interest in methods that compute a high b-factor image using
only low and intermediate b-factor scans [61]. This ‘computed high b-value DWI’ uses a diffusion
model (most commonly ADC, but kurtosis and IVIM have been used) to produce high contrast
diffusion-weighted images with lower noise than images actually acquired with the high b-factor.
There are variable reports of diagnostic value [62,63], and again, possible effects of diffusion time
differences have been neglected. Computation of a high b-factor image should be regarded as a noise
reduction technique since the computed image contains no information that is not present in the
actually acquired low and intermediate b-factor scans. ‘Apparent high b-value DWI’ would be more
appropriate term for this model-based technique [64].
7. Compartment Models
7.1. Two-Compartment Models
Compartment models aim to make a direct assignment of the microstructural features that
cause signal changes. Ideally the model components will relate closely to diagnostic tissue features.
A common approach uses compartment models that describe the DWI signal as the sum of separate
signals arising from separate (non-mixing) populations of water molecules in distinct structural
environments. Most previous studies have quantified properties of neural tissue [65,66], but recent
applications of structural models to the diffusion signals of non-neural tissue show promise.
The intravoxel incoherent motion (IVIM) model (see Section 5.2) separates the signals from
vascular and non-vascular water, however, its description of diffusion in the cellular component
of the tissue does not account for the known presence of two clearly distinct “slow” and “fast”
diffusion environments. This deficiency of the IVIM model may be responsible for inconsistent
estimates of the fast and slow diffusion parameters [49,52,67].
7.2. A Three-Compartment Model: VERDICT
The recent VERDICT (Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours)
framework addresses some of the limitations of the IVIM model by using two isotropic components to
describe the non-vascular diffusion environment [68]. Significantly, VERDICT addresses the diffusion
time dependence of the signal attenuation by modeling the intracellular space as an impermeable
spherical pore. For in vivo data the inherently low signal-to-noise ratio necessitates model fitting based
on fixed diffusion coefficients and the model provides estimates of f EES (extracellular/extravascular
space volume fraction), f IC (intracellular (IC) volume fraction), f VASC (vascular volume fraction),
and R (cell radius). f IC/R3 provides a measure of cell density.
A preclinical application of VERDICT in a colorectal cancer model [68] provided estimates of
cancer cell size (R), cell density ( f IC/R3), and vascular volume ( f VASC) in close agreement with
histology. More importantly, these parameters distinguished tumour cell lines and detected the effects
of chemotherapy, while the standard ADC and IVIM techniques failed. An in vivo pilot of prostate
cancer showed qualitatively good discrimination of cancer and benign tissue [58], however, this study
used long imaging protocols which are not feasible for routine clinical use. More recently an accelerated
VERDICT protocol for prostate [69] was developed using an optimization technique [70] to identify
a feasible measurement protocol that accommodates clinical and hardware constraints.
One of the current limitations of VERDICT is the neglect of diffusion anisotropy in the prostate.
A possible reason for inconsistent results from DTI-based estimates of diffusion anisotropy (see Section 5.1),
separate from the highly heterogeneous stromal fiber orientation, is the masking of sub-voxel diffusion
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anisotropy by the presence of a significant ‘background’ pool of water having isotropic diffusion
dynamics. This possibility has been addressed in a study of whole prostates ex vivo that compared
ten different compartment models [41]. This study found that under all measurement conditions tested
the highest information content models were those that included both an isotropic restricted diffusion
component and an unrestricted anisotropic component. Fractional anisotropy (FA) calculated from the
anisotropic component of the two-component models was higher than FA calculated from the DTI
model—indicating the presence of a masking effect. It remains to be determined whether this more
sensitive anisotropy detection method has any diagnostic value.
The ex vivo prostate study [41] supported the generality and broad applicability of VERDICT in
several ways:
• Model selection results were largely independent of voxel size—indicating that the successful
modeling of ‘true’ diffusion in the non-vascular space as one restricted and one unrestricted
compartment is not strongly dependent on the amount of subvoxel structure heterogeneity.
• Model selection results were largely independent of maximum b-factor.
• The diffusivity parameters were not fixed during model fitting in the ex vivo study, but still
returned average values similar to the fixed diffusivities used in fitting VERDICT to the relatively
noisy in vivo data. This provides an independent validation of the fixed values used for the in vivo
data fitting.
8. Future Directions
The role of DWI in prostate pathology assessment is in a very early stage of development and
although demonstrably effective, the current standard ADC model could not be less sophisticated.
More advanced signal analysis models show promise of improved accuracy but in many cases have
not been appropriately tested and the DWI acquisition methods are inconsistent despite attempts to
implement a consensus-based standard. Incomplete reporting of critical measurement parameters may
be resulting in an underestimation of the diagnostic accuracy of DWI methods. Recent basic science
investigations have improved our understanding of the way prostate tissue microstructure determines
the nature of contrast in diffusion-weighted images, but significant issues remain. The priorities for
prostate DWI method development should address:
Diffusion time. The diffusion time dependence of DWI measurements needs to be clarified and
diffusion time reported in all published studies to enable controlled meta-analysis. The consensus
methods should include a specification of recommended diffusion time. At present only the
VERDICT method specifically accounts for and exploits the diffusion time dependence of
the signal.
Membrane permeability. At present, the multi-compartment structural models and multi-component
phenomenological models assume no exchange of water between the compartments/components
during the DWI measurement. Studies of a range of cell types in suspension found that
membrane permeability alterations produced significant effects on DWI model parameters [71,72].
Although technically challenging, incorporation of water exchange may be an important
component of DWI model optimization for clinical applications.
T2 relaxation. Current multi-component models also neglect or implement strategies to minimize
potential complications due to the possible presence of multiple water pools with different
spin-spin (T2) relaxation rates, despite evidence of their existence in prostate tissue [73–75].
There are, as yet, no studies that investigate whether the two main water pools identified in
diffusion analyses have a direct one-to-one correspondence with the apparently distinct T2
water pools.
Diagnostic accuracy. The complex diffusion dynamics of biological tissue means that appropriately
developed multi-component models are likely to supersede the current ADC method used in
prostate mpMRI. It is essential that assessment of the clinical performance of these models is
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based on testing of their total information content by using methods that correlate pathology
and tissue structure features with the combined model parameters.
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